Current disease phase-Chronic phase Posts on Medivizor
Navigation Menu

Current disease phase-Chronic phase Posts on Medivizor

Safety and effectiveness of unbranded imatinib in CML

Posted by on Oct 19, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the safety and effectiveness of switching from original brand imatinib (Gleevec) to generic imatinib in chronic myeloid leukemia (CML). The study found that switching from branded to generic imatinib is a safe option in these patients. Some background New medications on the market have a patent by their...

Read More

Evaluating nilotinib as a consolidation therapy for patients with chronic myeloid leukemia

Posted by on Sep 8, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to evaluate the effectiveness of nilotinib as a consolidation therapy for patients with chronic myeloid leukemia who had achieved a major response with imatinib. This study concluded that nilotinib led to safer, deeper responses in these patients. Some background Imatinib (Gleevec) is a tyrosine kinase inhibition (TKI)...

Read More

Can tyrosine kinase inhibitor treatment be stopped in CML patients with deep molecular response?

Posted by on May 29, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to define the conditions necessary for stopping tyrosine kinase inhibitor treatment in patients with chronic myeloid leukemia. This study concluded that patients who maintain a deep molecular response have good molecular relapse-free survival and can be considered for treatment discontinuation. Some...

Read More

How safe and effective is ponatinib for chronic phase chronic myeloid leukemia patients?

Posted by on Apr 18, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness and safety of ponatinib (Iclusig) for patients with chronic phase chronic myelogenous leukemia. This study concluded that ponatinib is safe and effective in this group of patients. Some background The Philadelphia chromosome (BCR-ABL1) is found in almost all patients with chronic...

Read More

Nilotinib versus dasatinib: Comparing side effects

Posted by on Feb 23, 2018 in Leukemia | 0 comments

In a nutshell This study compared side effects between two similar therapies – nilotinib (Tasigna) and dasatinib (Sprycel) – for chronic myeloid leukemia (CML). Researchers reported more serious side effects with dasatinib than with nilotinib. Some background Tyrosine kinase inhibitor (TKI) therapy is a standard first-line treatment...

Read More

Chromosomal abnormalities at diagnosis does not predict long-term treatment outcomes with tyrosine kinase inhibitors

Posted by on Jan 28, 2018 in Leukemia | 0 comments

In a nutshell This study examined whether chromosomal abnormalities at diagnosis can predict treatment outcomes with TKIs in chronic myeloid leukemia (CML). Researchers reported similar long-term treatment outcomes in patients with and without chromosomal abnormalities at diagnosis. Some background CML is a disease in which the bone marrow makes...

Read More

An analysis comparing reduced-intensity conditioning and myeloablative therapy for CLL

Posted by on Dec 30, 2017 in Leukemia | 0 comments

In a nutshell This study analyzed the results of 37 studies comparing myeloablative therapy and reduced intensity conditioning (RIC) before stem cell transplantation in patients with chronic lymphocytic leukemia (CLL). This study concluded that RIC was associated with lower mortality and better survival compared to myeloablative therapy. Some...

Read More

Modern treatment approaches for chronic-phase CML

Posted by on Oct 25, 2017 in Leukemia | 0 comments

In a nutshell This study reviewed evidence of novel agents in the treatment of chronic myeloid leukemia (CML). Some background CML is a disease in which the bone marrow makes too many mature and immature white blood cells. It is typically a slowly progressing disease that occurs mainly during or after middle age. Most patients are diagnosed in the...

Read More